PBF-1129

PBF-1129 is an orally bioavailable small molecule antagonist of the adenosine A2B receptor (ADORA2B), a key immunomodulatory checkpoint molecule. By selectively blocking the adenosine A2B receptor, PBF-1129 disrupts adenosine-mediated immunosuppression in the tumor microenvironment, leading to potential anti-inflammatory, immunomodulating, and antineoplastic effects. Preclinical studies have shown that it reduces tumor growth and metastasis by decreasing signaling pathways associated with cell survival and proliferation. Inhibition of this receptor also reduces expression of CD39 and CD73 on antigen-presenting cells, decreases myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), thereby enhancing antitumor immunity. The drug has demonstrated efficacy both as monotherapy and in combination with immune checkpoint inhibitors such as anti-PD-1 therapies. Developed by Palobiofarma in collaboration with Ohio State University, its primary clinical indication is non-small cell lung cancer.

Other names

EVT-278912EVT278912EVT 278912